Plasma Fractionation Market Revenue to Cross USD 12 billion by 2035 | Roots Analysis

Published: December 2023


According to a recently published report by Roots Analysis, the growing prevalence of  rare and chronic disorders is driving the plasma fractionation market growth

Plasma Fractionation Industry Overview

The global plasma fractionation market is anticipated to grow at a CAGR of 10% from 2023-2035, reaching USD 12.7 billion by 2035.

Plasma fractionation is a process that is employed to purify and separate plasma into individual protein components. These fractionates are then purified, which can further be used as therapeutic medicines, known as plasma-derived therapies or plasma-derived medicinal products. This involves a sequence of processes, including precipitation / chromatography, purification, and virus-inactivation.  Fractionation is a highly developed bioprocess that can be carried out from small scale to commercial scale production.  Plasma fractionation methods usually involve alteration of  physical and chemical properties of plasma, which leads to change in solubility, and ultimately, the precipitation of target proteins. In some cases, the precipitation of plasma proteins is carried out through cryoprecipitation, a controlled temperature change method. Additionally, the protein precipitation process is facilitated by the addition of a precipitation or a separation agent. Once the proteins have been precipitated, they can be isolated using mechanical or chemical separation methods.  It is worth highlighting that more than 30 unique therapeutic plasma proteins have already been developed through plasma fractionation which helps to treat various indications.

Browse 105+ figures and 130+ market data tables spread across 185+ pages and detailed Table of Content on “Plasma Fractionation Market by Type of Company, Scale of Operation, Type of Plasma-derived Therapeutic Products Manufactured, Therapeutic Areas of Plasma-derived Products and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/plasma-fractionation-market.html

Market Drivers

Various factors contribute to the market growth of plasma fractionators. These factors include growing demand for immunoglobulins and the increasing burden of bleeding disorders. Owning to the increasing burden of bleeding disorders, there is an evident surge in the need for safe and effective blood components. Plasma fractionates are used being for the treatment of various immunological, hematological and neurological disorders. Owing to the growing burden of the aforementioned disorders, the demand for effective therapies is anticipated to increase and is likely to present a lucrative opportunity for the plasma fractionators.

Market Restraints

One of the primary restraints associated with this industry include the development of recombinant alternatives. In several developed nations, the recombinant factors have made a strong footprint. These recombinant factors offer extended half-life and last longer in the body as compared to the conventional blood products. Moreover, the demand for these recombinant factors has increased in the developing nations such as Brazil, India and China. Owing to the afore-mentioned factors, the expansion of plasma fractionation market size is anticipated to face some limitations.

Growth Factors

Despite the challenges, several growth factors continue to drive the plasma fractionation market forward. One notable factor is the strategies adopted by the government to increase the regional self-sufficiency. Over the years, governments of various regions have been focused on increasing the regional self-sufficiency for plasma fractionates. These approaches have been designed to increase the availability of plasma fractionates within the region and to increase domestic production. Given the effort of government bodies and growing usage of these products, the market size of the plasma fractionation market is anticipated to observe a significant growth.

Plasma Fractionation Market Segments

Based on the type of company, the market is segmented into In-House Manufacturers and Contract Service Providers.

  • The in-house manufacturers segment led the plasma fractionation market, capturing the largest revenue share of close to 95.0% in 2023.
  • The contract service providers is anticipated to show the highest market growth potential during the forecast period of over 14% annually.

Based on the scale of operation, the market is segmented into Preclinical, Clinical and Commercial.

  • The commercial scale led the plasma fractionation market, capturing the largest revenue share of close to 88.0% in 2023.
  • Both, commercial and preclinical segments are anticipated to show the highest market growth potential during the forecast period of over 9.5% annually.

Based on the type of plasma-derived therapeutic products manufactured, the market is segmented into Albumins, Coagulation Factors, Immunoglobulins, Protease Inhibitors and Other Plasma derived Products.

  • The immunoglobulin segment led the plasma fractionation market, capturing the largest revenue share of more than 50.0% in 2023.
  • In fact, the immunoglobulin segment is anticipated to show the highest growth potential by growing at a CAGR of over 10.5% during the forecast period.

Based on the therapeutic areas of plasma-derived products, the market is segmented into Hematological Disorders, Hepatic Disorders, Immunological Disorders, Neurological Disorders and Other Disorders.

  • The immunological disorders segment led the plasma fractionation market, capturing the largest revenue share of more than 45.0% in 2023.
  • The neurological segment is anticipated to show the highest growth potential by growing at a CAGR of over 10% during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World

  • In terms of the demand across key geographical regions, North America dominated the plasma fractionation market and accounted for the largest revenue share of close to 45.0% in 2023.
  • In Asia-Pacific, the plasma fractionation market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The plasma fractionation market report also includes detailed profiles of key players (listed below) that have the capability to perform plasma fractionation:

  • Baxter
  • Grifols
  • Kedrion
  • Octapharma
  • CSL
  • Takeda Pharmaceutical

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/plasma-fractionation-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Blog: https://www.rootsanalysis.com/blog/unveiling-the-future-of-liquid-biopsy-market/

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry